Mark Rixon

Mark is a practiced biotechnology professional with 30 years of industrial experience focusing on recombinant protein expression, antibody generation, and protein engineering. Mark has made significant contributions to the development of therapeutic protein candidates currently in Phase II and Phase III clinical trials and pre-clinical development, including recombinant monoclonal antibodies, receptor-Fc fusion proteins, and bispecific antibodies. Presently, Mark is Sr. Director of Protein Therapeutics at Alpine Immune Sciences, a biotechnology company developing IgSF receptor-Fc fusion proteins as biotherapeutics in autoimmune and immuno-oncology applications. Prior to joining Alpine Immune Sciences, Mark worked for 19 years at ZymoGenetics in the Protein Biochemistry and Protein Sciences groups focusing on biopharmaceutical hit validation, lead candidate characterization, and optimization of clinical candidate molecules. Prior to his tenure at ZymoGenetics, Mark worked in the biotechnology division at The Dow Chemical Company developing oncology-focused recombinant antibody clinical candidates. Mark received his Ph.D. in biochemistry from the University of Washington which he followed with a Post-Doctoral fellowship at The Fred Hutchinson Cancer Research Center in Seattle, WA.